A global demand for clean-label relief
If you’ve ever experienced the creeping stiffness after a long day of sitting or felt that familiar tug in your back when you bend to pick something up, you know how disruptive day-to-day discomfort can be. Back pain and joint stiffness are not just occasional annoyances; they are among the leading causes of physical limitation worldwide, affecting hundreds of millions around the globe. Low back pain alone impacts over 619 million people and is projected to reach 843 million by 2050 as the population ages.1,2
While conventional approaches like anti-inflammatory drugs or physical therapies may help, these solutions can be both time-consuming and cost-prohibitive for many consumers. These barriers, coupled with a renewed “back to nature” approach, are driving demand for botanical alternatives that deliver both efficacy and safety, especially plant-based, clinically substantiated, clean-label solutions.3 As pain and inflammation pathways are better understood, formulators increasingly seek innovations that modulate key biological targets rather than merely masking symptoms.
Two Ayurvedic powerhouses, one synergistic solution
For centuries, Ayurveda has revered Curcuma longa (curcumin) and Boswellia serrata (boswellia) as potent allies for supporting joint mobility, flexibility, and overall physical comfort. When combined, their complementary bioactive profiles (curcuminoids and AKBA, respectively) amplify benefits for comprehensive musculoskeletal support.
That dual power is now harnessed in Tenzara, Akay Bioactives’ new synergistic complex that merges time-honoured wisdom with modern delivery innovation.
Powered by FenuMat technology for superior bioavailability
At the heart of Tenzara is Akay’s patented FenuMat technology, a clean-label matrix derived from soluble fenugreek fibre. This innovative delivery system enhances the solubility, stability, and bioavailability of bioactives, dramatically improving their absorption and therapeutic effects. Pharmacokinetic data from a preliminary formulation showed a 24.8x increase in ‘free’ curcuminoid bioavailability and a 6.9x increase in AKBA versus standard extracts.4,5 This allows for a low, once-daily 400 mg dose that maintains efficacy while supporting clean-label simplicity.
Multi-pathway support for whole-body comfort
Unlike traditional botanicals that act on a single target, Tenzara engages multiple physiological pathways. By simultaneously modulating COX-2, 5-LOX, NLRP3, and IL-1β, it helps regulate both the inflammatory and innate-immune responses. The goal: to restore balance at the cellular level and support resilience against everyday physical stressors.
Clinically substantiated for rapid relief
In a randomised, double-blind, placebo-controlled clinical trial (Mamatha et al., 2025), participants taking Tenzara experienced notable improvements:
- 25.5% reduction in BASDAI scores after just two weeks
- 65.5% reduction in BASDI by day 28 vs. placebo
- Up to 70% improvement in stiffness and discomfort scores by day 14
Significant decreases in key inflammation biomarkers including: - NLRP3 reduced by 39.3%
- IL-1β reduced by 59.3%
These results demonstrate how Tenzara not only soothes symptoms but also acts upstream to modulate underlying biological processes.
Formulator-friendly and future-focused
Beyond established efficacy, Tenzara offers versatility and clean-label assurance for brand owners. The taste-minimised, water-dispersible powder integrates seamlessly into Vegan, non-GMO, kosher, and halal formulations in trending nutraceutical formats. Responsibly sourced and fully traceable, it delivers on both sustainability and efficacy, aligning with the evolving expectations of today’s health-conscious consumers.
Bridging tradition and technology
Rooted in Ayurveda and optimised through modern science, Tenzara redefines the potential of plant-based, musculoskeletal comfort. By bringing together two renowned botanicals with next-generation delivery technology, it provides fast-acting, long-lasting, comfort at a low, once-daily dose, ideal for consumers who want more from natural wellness.
References:
1. World Health Organization, 2023.
2. Global Burden of Disease Study, 2021.
3. American College of Physicians, 2017.
4. Abhilash et al., 2021.
5. Mamatha et al., 2025.